美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Dorsey Wright Healthcare Momentum ETF

62.02

+1.282.10%

盤前：62.020.00000.00%04:00 EDT

成交量：7.69萬

成交額：478.06萬

市值：2.92億

市盈率：20.29

高：62.86

開：61.98

低：61.88

收：60.74

52周最高：64.10

52周最低：39.76

股本：470.00萬

流通股本：470.00萬

量比：2.09

換手率：1.64%

股息：1.53

股息率：2.46%

每股收益(TTM):3.06

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

賽諾醫療：子公司輸送型球囊擴張導管獲醫療器械註冊證

東方海洋(002086.SZ)：清道夫受體-A(SR-A)測定試劑盒獲得醫療器械註冊證

美年健康在寧波投資成立數智科技公司

步步高等成立商貿公司

透景生命(300642.SZ)子公司取得醫療器械註冊證

凱普生物(300639.SZ)子公司取得醫療器械註冊證書

今天北交所新股百邁科申購，聚焦外科手術醫療器械領域

國家藥監局召開醫療器械臨床研究成果轉化暨「春雨行動」工作推進會

Roivant和Priovant推出新獲批的罕見病藥物Lisraya，每月售價35,000美元

美國FDA批准胰腺癌突破性藥物獨立藥企Revolution Medicines迎里程碑

环球市场播报

石藥集團在石家莊成立健康創新科技公司

Priovant宣佈FDA批准Lisraya™（Brepocitinib）用於成人皮肌炎治療；現已在美國上市

美國FDA批准了Roivant-Priovant公司的一款皮膚病藥物

Street View：Revolution的胰腺癌藥物獲批，開啓「變革性」時代

錦波生物中報遇冷：重組膠原蛋白龍頭高增長敍事遇考驗

傑富瑞：將Revolution Medicines目標價從242美元上調至270美元。

Brightspring Health Services Inc(BTSG)股票8月26日收盤上漲7.20%：背後推手曝光

TradingKey中文

Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露

美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河

BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/PTH/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":62.0224,"timestamp":1789675200000,"preClose":60.7441,"halted":0,"volume":76939,"hourTrading":{"tag":"盘前","latestPrice":62.0224,"preClose":62.0224,"latestTime":"04:00 EDT","volume":1,"amount":62.0224,"timestamp":1789718420500,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021044019089919753,"floatShares":4700000,"shares":4700000,"eps":3.057033,"marketStatus":"盤前交易","change":1.2783,"latestTime":"09-18 09:25:18 EDT","open":61.98,"high":62.86,"low":61.88,"amount":4780643.080622,"amplitude":0.016133,"askPrice":69.83,"askSize":100,"bidPrice":54.21,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.0224,"sharesOutstanding":2480000,"nav":60.77493,"aum":287465418.9,"dividendRate":0.024599,"bidAskSpread":0.00195,"preHourTrading":{"tag":"盘前","latestPrice":62.0224,"preClose":62.0224,"latestTime":"04:00 EDT","volume":1,"amount":62.0224,"timestamp":1789718420500,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":62.01,"preClose":62.0224,"latestTime":"19:30 EDT","volume":10,"amount":619.8306,"timestamp":1789687804886,"change":-0.0124,"changeRate":-0.0002,"amplitude":0},"volumeRatio":2.0859269999726906,"impliedVol":0.0354,"impliedVolPercentile":0.036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.0859269999726906,"shares":4700000,"dividePrice":1.5257,"high":62.86,"amplitude":0.016133,"preClose":60.7441,"low":61.88,"week52Low":39.76,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":62.0224,"eps":3.057033,"divideRate":0.024599,"volume":76939,"delay":0,"ttmEps":3.057033,"open":61.98,"prevYearClose":49.701,"fiveDayClose":60.5791,"twentyDayClose":64.0724,"sixtyDayClose":54.9982},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664858778","title":"賽諾醫療：子公司輸送型球囊擴張導管獲醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2664858778","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664858778?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 18:35","pubTimestamp":1788258920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEIH","MDEV","MEDX","LNGR","HART","GDOC","AGNG","RSPH","LGHT","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831017","title":"東方海洋(002086.SZ)：清道夫受體-A(SR-A)測定試劑盒獲得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831017","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831017?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:03","pubTimestamp":1788249802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东方海洋(002086.SZ)发布公告，公司全资子公司艾维可生物科技有限公司自主研发的清道夫受体-A(SR-A)测定试剂盒(磁微粒化学发光法)于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证。该产品用于体外定性测定人体血清、血浆中的清道夫受体-A(SR-A)。上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEIH","MEDX","GDOC","MDEV","159883","HART","RSPH","BK0046","BK0092","09996","BK1574","AGNG","BK1100","002086","PTH","BK1583","LNGR","BK0213","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831126","title":"美年健康在寧波投資成立數智科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831126","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831126?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:50","pubTimestamp":1788249053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDEV","LNGR","GDOC","IEIH","HART","RSPH","LGHT","PTH","MEDX","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664880657","title":"步步高等成立商貿公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2664880657","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664880657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 11:46","pubTimestamp":1788234379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","MDEV","LNGR","AGNG","LGHT","PTH","HART","RSPH","MEDX","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074020","title":"透景生命(300642.SZ)子公司取得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:34","pubTimestamp":1788172480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)发布公告，公司控股子公司河北透景生命科技有限公司于近日取得国家药品监督管理局颁发的1项医疗器械注册证，产品为曲霉半乳甘露聚糖检测试剂盒(磁微粒化学发光法)。该产品可用于体外定性检测人血清或肺泡灌洗液样本中的曲霉半乳甘露聚糖，其检测结果用于曲霉感染的辅助诊断。此次医疗器械注册证的取得，将进一步增强公司及子公司在真菌检测领域的综合竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK0046","LGHT","RSPH","BK0042","LNGR","MDEV","09996","BK1100","BK0239","159883","HART","300642","IEIH","MEDX","PTH","BK1583","BK1574","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075807","title":"凱普生物(300639.SZ)子公司取得醫療器械註冊證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075807","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663075807?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 16:36","pubTimestamp":1788165374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯普生物(300639.SZ)发布公告，近日，公司的全资子公司潮州凯普生物化学有限公司(简称“凯普化学”)取得国家药品监督管理局颁发的《中华人民共和国医疗器械注册证(体外诊断试剂)》，产品名称：基孔肯雅病毒/登革病毒核酸检测试剂盒(荧光PCR法)，该产品用于体外定性检测人血清或血浆样本中的基孔肯雅病毒和登革病毒的核酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0132","BK1583","300639","HART","BK1100","LGHT","GDOC","159883","AGNG","RSPH","MDEV","PTH","BK0042","BK0046","IEIH","09996","BK0239","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663208770","title":"今天北交所新股百邁科申購，聚焦外科手術醫療器械領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2663208770","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663208770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 14:57","pubTimestamp":1788159461,"startTime":"0","endTime":"0","summary":"顶格申购所需资金约811万元","market":"us","thumbnail":"https://img3.gelonghui.com/6cf81-9c6111b2-4705-4ed4-93b5-2372ef807bf8.jpg?guru_height=852&guru_width=1280&guru_size=179202","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/6cf81-9c6111b2-4705-4ed4-93b5-2372ef807bf8.jpg?guru_height=852&guru_width=1280&guru_size=179202"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6430275","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1100","MDEV","BK1583","AGNG","HART","RSPH","159883","MEDX","LNGR","GDOC","09996","PTH","LGHT","BK1574","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663002935","title":"國家藥監局召開醫療器械臨床研究成果轉化暨「春雨行動」工作推進會","url":"https://stock-news.laohu8.com/highlight/detail?id=2663002935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663002935?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 10:38","pubTimestamp":1788143908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","RSPH","GDOC","LGHT","PTH","AGNG","MDEV","MEDX","IEIH","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662965140","title":"Roivant和Priovant推出新獲批的罕見病藥物Lisraya，每月售價35,000美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662965140","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662965140?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 21:43","pubTimestamp":1787924608,"startTime":"0","endTime":"0","summary":"更新 1-Roivant和Priovant推出新获批的罕见病药物Lisraya，每月售价35,000美元全文补充了详细信息和背景路透8月28日-Roivant公司及其合作伙伴Priovant Therapeutics于周五将新获批的罕见病药物Lisraya的30天用量定价为35,000美元。皮肌炎是一种罕见疾病，会引起疼痛性皮疹和进行性肌肉无力。Roivant持有Priovant 71%的股权，而辉瑞持有24%的股份。合作方预计，Lisraya在美国的市场独占权将至少持续至2039年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4S44P14K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美國FDA批准胰腺癌突破性藥物 獨立藥企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061828?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE0009355771.USD","BK4585","IE0002141913.USD","IE0009354923.USD","IE00BFTCPJ56.SGD","LABU","BBH","CANC","IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","RVMD","PTH","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4588","BK4139","IE00BJT1NW94.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662059157","title":"石藥集團在石家莊成立健康創新科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2662059157","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662059157?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 13:58","pubTimestamp":1787896694,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","HART","LGHT","RSPH","LNGR","PTH","MEDX","IEIH","AGNG","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141500682","title":"Priovant宣佈FDA批准Lisraya™（Brepocitinib）用於成人皮肌炎治療；現已在美國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1141500682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141500682?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 03:29","pubTimestamp":1787858949,"startTime":"0","endTime":"0","summary":"Priovant今日宣布，美国食品药品监督管理局（FDA）已正式批准Lisraya™（Brepocitinib）用于治疗成人皮肌炎患者。这一里程碑式的决定意味着该药物现已即刻在美国市场供应。\n皮肌炎是一种罕见的自身免疫性疾病，以肌肉无力和特征性皮疹为主要表现，长期以来困扰着众多患者。此次获批为这一患者群体带来了全新的治疗选择。\nLisraya™作为一种创新疗法，其获批上市标志着皮肌炎治疗领域取得了重大突破。该药物目前已可及，符合条件的患者将能够立即获得这一新的治疗方案的处方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662308069","title":"美國FDA批准了Roivant-Priovant公司的一款皮膚病藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2662308069","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662308069?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 03:26","pubTimestamp":1787858803,"startTime":"0","endTime":"0","summary":"美国FDA批准了Roivant-Priovant公司的一款皮肤病药物路透8月27日-美国食品和药物管理局周四表示，已批准Roivant公司（ROIV.O）及其合作伙伴Priovant Therapeutics公司研发的一种用于治疗皮肌炎的药物，这使其成为首款用于治疗该皮肤病的口服药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O1TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704894","title":"Street View：Revolution的胰腺癌藥物獲批，開啓「變革性」時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704894","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662704894?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 19:36","pubTimestamp":1787830591,"startTime":"0","endTime":"0","summary":"BUZZ-Street View：Revolution的胰腺癌药物获批，开启“变革性”时代8月27日-** Revolution Medicines旗下RVMD.O公司研发的、具有突破性的  胰腺癌药物Rasonque于周三获得美国FDA批准** RVMD股价盘前上涨3%，报222美元；该股平均评级为“买入”，目标价中位数为240美元——路孚特数据** 监管部门批准后，至少有7位分析师上调了目标价化疗后时代来临？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4T44O15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0109394709.USD","IE0009354923.USD","BBH","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","IE0002141913.USD","PTH","CANC","RVMD","IDNA","IE0009355771.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662677438","title":"錦波生物中報遇冷：重組膠原蛋白龍頭高增長敍事遇考驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2662677438","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662677438?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:36","pubTimestamp":1787819760,"startTime":"0","endTime":"0","summary":"近日，重组胶原蛋白头部企业锦波生物发布2026年半年报。02高毛利光环之下，行业周期与研发投入暗藏长期风险锦波生物依旧拥有行业内较高毛利率，但是高毛利已经难以维持高增长，赛道内卷正在逐步侵蚀原有优势。同行对比来看，巨子生物占据营收龙头位置，创尔生物处于规模爬坡阶段，行业竞争进一步加剧，锦波生物高毛利优势正被增长乏力抵消。对于锦波生物而言，护肤品业务的增长，暂时无法弥补医疗器械主业的下滑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-27/doc-iniptxkt9108819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEIH","LGHT","RSPH","09996","GDOC","MEDX","AGNG","HART","PTH","BK1574","LNGR","MDEV","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722025","title":"傑富瑞：將Revolution Medicines目標價從242美元上調至270美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722025?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 11:50","pubTimestamp":1787802605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","IE0009354923.USD","IE00BJJMRZ35.SGD","IDNA","BK4139","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","PTH","UUP","IE00B4R5TH58.HKD","CANC","LU0889565916.HKD","UDN","IE0009355771.USD","BBH","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662195744","title":"Brightspring Health Services Inc(BTSG)股票8月26日收盤上漲7.20%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2662195744","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662195744?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 04:16","pubTimestamp":1787775368,"startTime":"0","endTime":"0","summary":"• BrightSpring公布了强劲的第二季度营收，并上调了全年业绩指引。\n• 华尔街分析师维持“买入”评级，平均目标价为78.97美元。\n• 全年营收达129.1亿美元，净利润为1.9067亿美元。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262133913-market-movers-btsg-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2089984988.USD","LU2468319806.SGD","BTSG","BK4196","PSCH","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164882019?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","PTH","BBH","IE00B2B36J28.USD","IDNA","IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","LU0109394709.USD","CANC","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","RVMD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156385670?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","RVMD","IDNA","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","CANC","IE0009355771.USD","IE0009354923.USD","BBH","IE00B4R5TH58.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662436927","title":"BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662436927","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662436927?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 23:45","pubTimestamp":1787759102,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI下跌0.25%，报53,444.86点。标普500指数.SPX下跌0.02%，报7,675.90点；纳斯达克综合指数.IXIC下跌0.20%，报26,098.72点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N1B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","BK4094","BBH","PTH","IDNA","CANC","IE0009355771.USD","RVMD","WSM","IE0002141913.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4139","LU0868494708.USD","LU0889565916.HKD","BK4588","ANF","LU0109394709.USD","LU0868494617.USD","BK4178","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","LU0170899867.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}